Key Highlights
- CTSO shares fell in a session with no single confirmed public catalyst tied to that specific day.
- Full-year 2025 Revenue was approximately $37 million, up modestly year over year, with a net loss that narrowed substantially versus 2024.
- The company is preparing a new De Novo FDA submission for DrugSorb-ATR, targeting late 2026 or early 2027.
- Second-quarter 2026 revenue was around $9.6 million with gross Margin expanding toward 73%, following a reported Reverse Stock Split to maintain Nasdaq compliance.
A blood-purification pioneer with a commercial product in Europe and a long-sought U.S. approval still in reach, CytoSorbents Corporation (NASDAQ: CTSO) has become a study in how hard the last mile of regulatory access can be. Another single-session slide has drawn fresh attention to a company whose Market Value has shrunk dramatically over the past year even as revenue grows and losses narrow. For CTSO, the day-to-day noise sits atop a pivotal, still-unresolved U.S. regulatory story.
Company and Latest Development
CytoSorbents develops blood-purification technology for critical care and cardiac surgery. Its flagship CytoSorb device is used to remove inflammatory substances from blood and is marketed internationally, while its DrugSorb-ATR product is aimed at removing the blood thinner in cardiac-surgery patients. On 6 August 2026 the company reported second-quarter 2026 results, following first-quarter results in May. In March 2026 it announced the launch of its HotSwap product and a renewed distribution Partnership with Aferetica. The company has been working through the FDA process for DrugSorb-ATR, and per its first-quarter update it is preparing a new De Novo submission targeting late 2026 or early 2027.
What Is Driving Attention Around CTSO?
CTSO is down in a session, but no single confirmed public catalyst is tied to that specific day. The larger context is a stock that market-data providers show has fallen roughly two-thirds over the past year, alongside a reported reverse stock split undertaken to maintain Nasdaq minimum-bid compliance. With a very small market value and a binary U.S. regulatory outcome ahead, sentiment can shift sharply on limited news. Rather than assign the drop to any one event, it is more accurate to view it as heightened Volatility in a deeply de-rated small cap.
Key Numbers and Company Position
Full-year 2025 revenue was approximately $37 million, up modestly year-over-year, with a net loss that narrowed substantially versus 2024. First-quarter 2026 revenue was about $8.9 million, up 2%, with a gross margin near 69%; market-data sources put second-quarter 2026 revenue around $9.6 million with gross margin expanding toward 73%. The snapshot lists a Market Capitalisation near $19.9 million at about $6.33 per share; that valuation and share count are consistent with the reported reverse split.
What Could Come Next?
The defining catalyst is the DrugSorb-ATR U.S. regulatory pathway. The company has signalled a new De Novo submission targeting late 2026 or early 2027, so timing, submission progress and any FDA feedback are key items to watch. Beyond that, investors may monitor continued CytoSorb revenue growth internationally, uptake of the HotSwap launch and the Aferetica partnership, margin trends, and the next quarterly update.
Risks to Watch
The risks are substantial. U.S. regulatory success for DrugSorb-ATR is not assured, and prior FDA setbacks in this program show how uncertain the path can be; further delays would weigh on the Investment case. As an unprofitable company, CytoSorbents faces funding and dilution risk. The reported reverse split and steep share-price decline highlight listing-compliance and sentiment pressures.
A Pending De Novo Submission Is the Defining Catalyst Ahead
CytoSorbents Corporation enters late 2026 as a commercial-stage blood-purification company with growing revenue, narrowing losses and a pivotal U.S. regulatory decision still pending for DrugSorb-ATR. The slide has no single confirmed catalyst and is best read as volatility in a heavily de-rated small cap. The concrete milestones to monitor are the timing and outcome of the planned De Novo submission, revenue and margin trends, and the company's financing position.






Please wait processing your request...